Literature DB >> 8411386

Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators.

J Kamine1, T Subramanian, G Chinnadurai.   

Abstract

We have previously shown that the Tat protein of the human immunodeficiency virus type 1 (HIV-1) is a modular transcriptional activator that can be targeted upstream of either a synthetic promoter or the intact HIV promoter to activate transcription. This activation was shown to be largely dependent on the presence of consensus binding sites for the cellular transcription factor Sp1. Since the use of heterologous promoters may provide further insight into Tat-mediated transactivation, we have analyzed the transactivation of the thymidine kinase promoter of herpes simplex virus by Tat and by the acidic transcriptional transactivator VP16. The effects of mutations of defined upstream promoter elements show that Tat transactivation is dependent on Sp1 binding sites in a site-specific manner. In contrast, transactivation by the acidic transactivator VP16 is completely independent of any of the defined promoter elements upstream of the TATA box. These results suggest that Tat and the classically defined modular acidic transcriptional activators have different modes of transactivation. In addition, the substitution of the HIV-1 TATA box for the thymidine kinase TATA box substantially increases Tat transactivation, indicating that Tat transactivation may also ultimately involve TATA box-associated cellular transcription factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411386      PMCID: PMC238127     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.

Authors:  L S Tiley; S J Madore; M H Malim; B R Cullen
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

Review 2.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

Authors:  K M Weeks; C Ampe; S C Schultz; T A Steitz; D M Crothers
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

4.  The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters.

Authors:  R Ratnasabapathy; M Sheldon; L Johal; N Hernandez
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

5.  Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.

Authors:  M J Selby; B M Peterlin
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

6.  Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.

Authors:  C Southgate; M L Zapp; M R Green
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

7.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

8.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.

Authors:  S Roy; U Delling; C H Chen; C A Rosen; N Sonenberg
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

9.  TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter.

Authors:  B Berkhout; A Gatignol; A B Rabson; K T Jeang
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

10.  HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  8 in total

1.  Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.

Authors:  A Gatignol; M Duarte; L Daviet; Y N Chang; K T Jeang
Journal:  Gene Expr       Date:  1996

2.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 3.  T helper cell activation and human retroviral pathogenesis.

Authors:  K F Copeland; J L Heeney
Journal:  Microbiol Rev       Date:  1996-12

4.  Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat.

Authors:  R F Chun; O J Semmes; C Neuveut; K T Jeang
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Human GLI-2 is a tat activation response element-independent Tat cofactor.

Authors:  C M Browning; M J Smith; N M Clark; B R Lane; C Parada; M Montano; V N KewalRamani; D R Littman; M Essex; R G Roeder; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  ZASC1 stimulates HIV-1 transcription elongation by recruiting P-TEFb and TAT to the LTR promoter.

Authors:  James W Bruce; Rachel Reddington; Elizabeth Mathieu; Megan Bracken; John A T Young; Paul Ahlquist
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

7.  Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.

Authors:  Hao K Lu; Lachlan R Gray; Fiona Wightman; Paula Ellenberg; Gabriela Khoury; Wan-Jung Cheng; Talia M Mota; Steve Wesselingh; Paul R Gorry; Paul U Cameron; Melissa J Churchill; Sharon R Lewin
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

8.  CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes.

Authors:  Emmanuelle Wilhelm; Marie-Christine Doyle; Isaac Nzaramba; Alexandre Magdzinski; Nancy Dumais; Brendan Bell
Journal:  Retrovirology       Date:  2012-07-26       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.